In its fourth-quarter earnings investor presentation, Eli Lilly (LLY) highlighted its newer products such as Emgality, Verzenio, Olumiant, Lartruvo, Taltz, Basaglar, Jardiance, Trulicity, and Cyramza as key drivers of the company’s 11% YoY volume growth in fiscal 2018. In fiscal 2018, newer products reported 13.7% YoY volume growth, while the generic erosion of Cialis had the highest negative impact, close to 4.5%, on the overall YoY volume growth of the company.
Major revenue drivers
In fiscal 2018, Trulicity’s global sales were at $3.20 billion, a YoY rise of 58%, driven by robust demand in US and international markets. At the end of fiscal 2018, the drug was a leading player in terms of total prescriptions in the GLP-1 class of drugs and accounted for 45% of the serviceable obtainable market (or SOM) in the US.
In fiscal 2018, Olumiant’s global sales were at $202.5 million driven by a successful commercial launch in Germany. The drug was launched in the rheumatoid arthritis indication in July 2018 in the US and has reported sales of $6.7 million. International markets accounted for $195.9 million worth of Olumiant’s revenues.
In fiscal 2018, Jardiance reported global sales of $658.3 million, a YoY rise of 47%. According to Eli Lilly’s fourth-quarter earnings investor presentation, the drug accounts for 43% of the SOM in terms of total prescriptions (or TRx) and 52% of the SOM in new to brand prescriptions (or NBRx) in the US market. Jardiance has emerged as a market leader in the US and has witnessed a 9% YoY rise in TRx and a 14% YoY rise in NBRx in the fourth quarter.
In fiscal 2018, Cymbalta contributed $708 million to Eli Lilly’s total revenues, a YoY decline of 6%.
Taltz reported sales of $937.5 million, a YoY rise of 68%, in fiscal 2018. The drug reported a YoY rise of 82% in TRx in the fourth quarter.